| 摘要 |
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III) as follows:;;wherein R1C, R2C, R4C, WC, YC, ZC, and GC, are defined herein. |
| 主权项 |
1. A compound of Formula (III)wherein
YC is N or CH; ZC is N or CH; WC is N or CH; LC is —CH2O—, —CH═CH—, or —(CH2)1-2—; R1C is selected from the group consisting of phenyl, pyridin-4-yl, thienyl, benzothiophenyl, benzofuranyl, and indolyl; wherein said benzothiophenyl, benzofuranyl, and indolyl are attached to the core (YZ)—(ZC) containing ring via its benzo ring; and wherein R1C is optionally independently substituted with one or two substituents selected from C1-4alkyl, methoxy, fluoro, cyano, di(C1-4alkyl)amino, or trifluoromethyl; R2C is C3-5cycloalkyl, C1-6alkyl, or cyano; R4C is hydrogen or chloro; GC is selected from the group consisting of hydrogen, bromo, C1-6alkyl, C1-6alkoxy, unsubstituted C3-7cycloalkyl, unsubstituted C3-7cycloalkoxy, unsubstituted C3-7cycloalkyl-methoxy, C2-6alk-1-en-1-yl, 3,3,3-trifluoropropoxy, (C1-6alkyl)thien-2-yl, difluorophenyl, dimethylphenyl, and a substituent selected from the group consisting of g1 to g9;or an enantiomer, diastereomer, or pharmaceutically acceptable salt form thereof. |
